Akero Therapeutics Inc Quick Ratio (AKRO) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Akero Therapeutics Inc   (NASDAQ: AKRO)

Akero Therapeutics Inc 's Quick Ratio

AKRO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Akero Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Akero Therapeutics Inc 's Quick Ratio to 15.48, Quick Ratio remained below Akero Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Quick Ratio than Akero Therapeutics Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 119 to 153.

Explain Quick Ratio?
How much Cash & cash equivalents AKRO´s has?
What are AKRO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AKRO Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change 10.07 % 93.75 % 40.25 % 76.51 % 52.18 %
Y / Y Cash & cash equivalent Change 2.87 % -2.35 % -24.05 % 35.1 % 29.3 %
Quick Ratio MRQ 15.48 12.29 16.17 18.69 16.57
AKRO's Total Ranking # 153 # 119 # 129 # 124 # 133
Seq. Current Liabilities Change -21.11 % 42.32 % 6.75 % -8.17 % 38.87 %
Seq. Cash & cash equivalent Change -0.6 % 8.16 % -7.64 % 3.6 % -5.65 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 42
Healthcare Sector # 61
Overall Market # 153


Quick Ratio Statistics
High Average Low
1589.62 89.41 6.77
(Sep 30 2019)   (Jun 30 2022)




Financial Statements
Akero Therapeutics Inc 's Current Liabilities $ 48 Millions Visit AKRO's Balance sheet
Akero Therapeutics Inc 's Cash & cash equivalent $ 738 Millions Visit AKRO's Balance sheet
Source of AKRO's Sales Visit AKRO's Sales by Geography


Cumulative Akero Therapeutics Inc 's Quick Ratio

AKRO's Quick Ratio for the trailling 12 Months

AKRO Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 49.51 % 65.38 % 52.35 % 61.88 % 44.73 %
Y / Y Cash & cash equivalent TTM Growth -0.74 % 4.35 % 9.78 % 49.67 % 55.18 %
Quick Ratio TTM 15.29 15.54 18.56 21.62 23.04
Total Ranking TTM # 3181 # 1446 # 2065 # 2229 # 2320
Seq. Current Liabilities TTM Growth 2.35 % 18.66 % 8.43 % 13.54 % 13.21 %
Seq. Cash & cash equivalent TTM Growth 0.71 % -0.62 % -6.96 % 6.59 % 5.87 %

Quick ratio ranking by company, industry and sector >> Back to AKRO Financial Strength Comparisons >> Go to Compare AKRO Quick Ratio to its Competitors

On the trailing twelve months basis Due to decline in Current Liabilities in the Q3 2025 to $47.65 millions, cumulative Quick Ratio decreased to 15.29 below the Akero Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 462 other companies have achieved higher Quick Ratio than Akero Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 1446 to 3181.

Explain Quick Ratio?
How much Cash & cash equivalents AKRO´s has?
What are AKRO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 463
Healthcare Sector # 894
Within the Market # 3181


trailing twelve months Quick Ratio Statistics
High Average Low
26.63 17 7.69
(Mar 31 2024)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Xbiotech Inc   41.34 $ 147.367  Millions$ 3.565  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Rapport Therapeutics Inc   35.84 $ 513.026  Millions$ 14.316  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Janux Therapeutics Inc   35.54 $ 988.993  Millions$ 27.831  Millions
Inhibitor Therapeutics Inc   34.01 $ 2.977  Millions$ 0.088  Millions
Disc Medicine Inc   33.50 $ 615.920  Millions$ 18.383  Millions
Roivant Sciences Ltd   32.77 $ 4,385.835  Millions$ 133.857  Millions
Mbx Biosciences Inc   32.47 $ 391.673  Millions$ 12.062  Millions
Upstream Bio Inc   31.28 $ 372.427  Millions$ 11.908  Millions
Repare Therapeutics Inc   30.54 $ 112.604  Millions$ 3.687  Millions
Keros Therapeutics Inc   28.78 $ 693.472  Millions$ 24.092  Millions
Contineum Therapeutics Inc   28.68 $ 182.407  Millions$ 6.361  Millions
Viking Therapeutics Inc   27.88 $ 714.570  Millions$ 25.630  Millions
Liquidia Corporation  26.17 $ 157.496  Millions$ 6.019  Millions
Edgewise Therapeutics inc   26.03 $ 563.340  Millions$ 21.646  Millions
Prothena Corporation Public Limited Company  25.09 $ 330.843  Millions$ 13.188  Millions
Immuneering Corporation  24.83 $ 227.563  Millions$ 9.164  Millions
Psyence Biomedical ltd   23.53 $ 7.150  Millions$ 0.304  Millions
Lava Therapeutics Nv  23.48 $ 99.364  Millions$ 4.231  Millions
Trevi Therapeutics Inc   22.29 $ 194.927  Millions$ 8.745  Millions
Ligand Pharmaceuticals Incorporated  21.76 $ 664.522  Millions$ 30.539  Millions
Aprea Therapeutics Inc   21.39 $ 13.718  Millions$ 0.641  Millions
Stoke Therapeutics Inc   21.34 $ 248.310  Millions$ 11.634  Millions
Cervomed Inc   20.23 $ 27.294  Millions$ 1.349  Millions
Pulmatrix Inc   19.25 $ 4.794  Millions$ 0.249  Millions
Terns Pharmaceuticals Inc   19.21 $ 295.635  Millions$ 15.387  Millions
Emmis Acquisition Corp   18.63 $ 1.446  Millions$ 0.078  Millions
Design Therapeutics Inc   18.43 $ 205.970  Millions$ 11.173  Millions
Neurogene Inc   18.04 $ 265.410  Millions$ 14.710  Millions

Date modified: 2026-09-08T15:11:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.